Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Research & Development (2016 - 2025)

Immucell's Research & Development history spans 16 years, with the latest figure at $758864.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 7.39% year-over-year to $758864.0; the TTM value through Dec 2025 reached $3.0 million, down 21.97%, while the annual FY2025 figure was $3.0 million, 21.97% down from the prior year.
  • Research & Development reached $758864.0 in Q4 2025 per ICCC's latest filing, up from $694311.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.3 million in Q3 2022 to a low of $694311.0 in Q3 2025.
  • Average Research & Development over 5 years is $996381.3, with a median of $1.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: rose 21.22% in 2022, then plummeted 40.05% in 2025.
  • A 5-year view of Research & Development shows it stood at $1.1 million in 2021, then dropped by 3.71% to $1.0 million in 2022, then rose by 6.58% to $1.1 million in 2023, then fell by 26.74% to $819393.0 in 2024, then fell by 7.39% to $758864.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Research & Development are $758864.0 (Q4 2025), $694311.0 (Q3 2025), and $831858.0 (Q2 2025).